Suicide risk and efficacy of antidepressant drugs: Reply

Archives of General Psychiatry

Volumn 70, Issue 1, 2013, Pages 124-125

  Gibbons, Robert D ^a   Brown, C Hendricks ^a,d   Hur, Kwan ^a,c   Davis, John M ^b   Mann, J John ^e,f  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c HINES VA HOSPITAL   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^f Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATOMOXETINE; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ANALYTICAL ERROR; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; CORRELATION ANALYSIS; DATA ANALYSIS; DEPRESSION; DRUG EFFICACY; HUMAN; LETTER; MAJOR DEPRESSION; REMISSION; RISK ASSESSMENT; STATISTICAL ANALYSIS; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84871950304     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.758     Document Type: Letter

References (3)

1. Gibbons RD, Brown CH, Hur K, Davis JM, Mann JJ. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012;69(6):580-587.
2. Vitiello B, Silva SG, Rohde P, Kratochvil CJ, Kennard BD, Reinecke MA, Mayes TL, Posner K, May DE, March JS. Suicidal events in the Treatment for Adolescents With Depression Study (TADS). J Clin Psychiatry. 2009;70(5):741-747.
3. Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012;69(6):572-579.